From 2019 to 2021, venture capitalists plowed $35 billion into biotech companies with advanced platform technologies that could transform the industry.1
The past few years have seen a boom in biotechnology sector investments. VC companies invested in 2,200 biotech start-ups worldwide in 2016; by 2021, that number had grown to 3,100.2
Biotech companies raised more than $34 billion globally in 2021, more than doubling the 2020 total of $16 billion. In fact, The global biotechnology market size is expected to reach USD 3,879.51 billion by 2030, registering a CAGR of 13.9% over the forecast period, according to a new report by Grand View Research, Inc.3
Experts say that biotech stocks may be excellent long-term investments, in part because of the lengthy time-to-market for many drugs, but also due to the fact that regulatory and clinical developments can serve as catalysts for generating gains, which we saw with last week’s impressive biotech profile gains after news of US patent claims gave the stock a huge leg up.
Introducing: Actinium Pharmaceuticals Inc.
NASDAQ: ATNM
Actinium Pharmaceuticals, Inc. (NASDAQ:ATNM) is a biopharmaceutical company that focuses on developing targeted therapies for the treatment of cancers. The company is headquartered in New York City, and its main focus is on developing drugs that can specifically target cancer cells while sparing healthy cells.
Investing.com signaled 11 technical indicators indicating a BUY ALERT for (NASDAQ:ATMN).
This is a huge potential breakout opportunity…
ATNM has a strong balance sheet with approximately $115 million of cash (Cash balance as of June 30, 2022).
ATNM – Rally is Heating Up as Bullish Ratings Remain Strong Including a $45.00 Price Target
The company also expects that its current cash and cash equivalents will be sufficient to fund its operations through mid-2025.
Since 2020 there has been a tremendous boom in the biotech arena and ATNM has the potential to emerge as a hidden gem, with limitless upside potential.
American Bulls.com has issued a “STAY LONG” rating for (NASDAQ:ATMN) – the previous BUY signal was issued on 02/14/2023, when the stock price was 13.3600. Since then, ATMN has risen by +2.99%
There are so many BULLish ratings as well as that staggering $45.00 price target!
William Blair said, “Pending positive results from the Phase III SIERRA study and successful regulatory interactions with the FDA, [Iomab-B] is poised to disrupt the $600 million preconditioning market in the United States and Europe.”
On Feb. 18, 2023, the company announced:
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
Then… an analyst at H.C. Wainwright has given the stock a $45 price target! This would be a gain of 350% for NASDAQ:ATNM….
Dr. Sergio Giralt, Deputy Head, Division of Hematologic Malignancies, Attending Physician, Adult BMT Service at Memorial Sloan Kettering Cancer Center, stated,
“The SIERRA trial results are an exciting advancement for older patients with active r/r AML and will be practice changing in how we treat these patients. I am thrilled to see a high percentage of Iomab-B patients who achieved durable remissions reaching the critical 2-year survival mark. Significant improvement in event-free survival and overall survival, with an excellent safety profile in the SIERRA trial, demonstrate the potential of Iomab-B becoming a new standard of care for active, r/r AML.”
Furthermore… In recent news….
Actinium Pharmaceuticals Inc. (NASDAQ: ATNM) has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes for Health (NIH), to develop Actimab-A for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies.
KEY COMPANY HIGHLIGHTS:
- Actinium Pharmaceuticals, Inc. (NASDAQ:ATMN) stock holds buy signals from both short and long-term moving averages, giving a positive forecast for the stock
- – Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm
- – In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients
- Approximately $116 million in cash and cash equivalents at the end of Q2 2022 expected to fund key value creating clinical, regulatory and R&D milestones through mid-2025
Actinium is a pioneer and leader in the field of Actinium-225 alpha therapies with an industry leading technology platform comprising over 190 patents and patent applications including methods of producing the radioisotope AC-225.
Iomab-B, Actinium’s lead asset, is being studied in the pivotal Phase 3 SIERRA clinical trial as an induction and conditioning agent in patients over the age of 55 with active relapsed or refractory Acute Myeloid Leukemia (AML) prior to receiving a bone marrow transplant (BMT), also known as a hematopoietic stem cell transplant or HSCT. The SIERRA trial completed patient enrollment in the third quarter of 2021. View highlights of Key Opinion Leaders discussing Iomab-B:
Actinium’s clinical pipeline is led by radiotherapies that are being applied to targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a bone marrow transplant (BMT), gene therapy or adoptive cell therapy, such as CAR-T, to enable engraftment of these transplanted cells with minimal toxicities.
Lead product candidate, I-131 apamistamab (Iomab-B) has been studied in over four hundred patients, including the pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning.
Actimab-A will be available at over 2,000 clinical trial sites under the Experimental Therapeutics Clinical Trials Network (ETCTN) and the National Clinical Trials Network (NCTN) that includes leading oncology network groups such as Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN), Southwest Oncology Group (SWOG) and the Alliance for Clinical Trials in Oncology.
Let’s talk about the key potential factors of investing in the biotech vertical…
- Potential for growth: Biotech companies are often at the forefront of innovation, creating new drugs, therapies, and medical technologies that can significantly improve patient outcomes. As a result, successful biotech companies can experience rapid growth, with the potential for high returns on investment.
- High demand: The demand for new and innovative treatments for a range of diseases and medical conditions is increasing, driven by demographic changes, advances in technology, and an aging population. Biotech companies are well-positioned to meet this demand, with a focus on developing new drugs and therapies that can improve patient outcomes.
- Strong intellectual property protection: Biotech companies often have a strong intellectual property portfolio, with patents and trademarks protecting their products and technologies. This can create a competitive advantage, making it more difficult for other companies to replicate their products and services.
- Government support: Governments often provide support for the biotech industry, such as through research grants, tax incentives, and regulatory frameworks that support the development and commercialization of new drugs and therapies. This can create a favorable environment for biotech companies to operate and grow.
- Mergers and acquisitions: Biotech companies are often attractive targets for mergers and acquisitions by larger pharmaceutical companies, which can offer significant premiums to acquire successful biotech companies.
Today’s alert hits all of these markers, but specifically, we’d like to touch on growth potential, and technology demand.
ATNM has received many bullish remarks and ratings, including from William Blair who has maintained an “outperform” rating on shares.
With several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity, we see massive upside potential for Actinium Pharmaceuticals, Inc stock to perform well in the short-term.
Sources:
- https://www.mckinsey.com/industries/life-sciences/our-insights/what-are-the-biotech-investment-themes-that-will-shape-the-industry
- https://www.mckinsey.com/industries/life-sciences/our-insights/what-are-the-biotech-investment-themes-that-will-shape-the-industry
- https://www.grandviewresearch.com/press-release/global-biotechnology-market
Disclaimer
Digital Marketing Agency of Record: GloBull Technologies Inc., (“GloBull”).
1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.
2) The Article was issued on behalf of and sponsored by Actinium Pharmaceuticals Inc. (NASDAQ: ATNM). GloBull, has or expects to receive from Actinium Pharmaceuticals Inc. (NASDAQ: ATNM) $7200.00 for 30 days (22 BUSINESS DAYS).
3) Statements and opinions expressed are the opinions of the author and not GloBull, its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by GloBull for this Article. GloBull was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. GloBull requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. GloBull, relies upon the authors to accurately provide this information and GloBull, has no means of verifying its accuracy.
4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to GloBull’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. GloBull does not render general or specific investment advice and the information on GloBull.com should not be considered a recommendation to buy or sell any security. GloBull, does not endorse or recommend the business, products, services, or securities of any company mentioned on GloBull.com.
5) GloBull, and its respective directors, officers and employees hold no shares for any company mentioned in the Article.
6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements.
These forward-looking statements include, among other things, statements relating to:
(a) revenue generating potential with respect to Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s industry;
(b) market opportunity;
(c) Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s business plans and strategies;
(d) services that Actinium Pharmaceuticals Inc. (NASDAQ: ATNM) intends to offer;
(e) Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s milestone projections and targets;
(f) Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s expectations regarding receipt of approval for regulatory applications;
(g) Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and
(h) Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s expectations regarding its ability to deliver shareholder value.
Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about:
(a) the ability to raise any necessary additional capital on reasonable terms to execute Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s business plan;
(b) that general business and economic conditions will not change in a material adverse manner;
(c) Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis;
(d) Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s ability to enter into contractual arrangements with additional Pharmacies;
(e) the accuracy of budgeted costs and expenditures;
(f) Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s ability to attract and retain skilled personnel;
(g) political and regulatory stability;
(h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms;
(i) changes in applicable legislation;
(j) stability in financial and capital markets; and
(k) expectations regarding the level of disruption as a result of CV-19.
Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance, or achievements of Actinium Pharmaceuticals Inc. (NASDAQ: ATNM) to be materially different from any future plans, intentions, activities, results, performance, or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation:
(a) Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations;
(b) public health crises such as CV-19 may adversely impact Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s business;
(c) the volatility of global capital markets;
(d) political instability and changes to the regulations governing Actinium Pharmaceuticals Inc. (NASDAQ: ATNM)’s business operations
(e) Actinium Pharmaceuticals Inc. (NASDAQ: ATNM) may be unable to implement its growth strategy; and
(f) increased competition.
Except as required by law, Actinium Pharmaceuticals Inc. (NASDAQ: ATNM) undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Actinium Pharmaceuticals Inc. (NASDAQ: ATNM) nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency, or completeness of the information in this document. Neither Actinium Pharmaceuticals Inc. (NASDAQ: ATNM) nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.
7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Actinium Pharmaceuticals Inc. (NASDAQ: ATNM) or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Actinium Pharmaceuticals Inc. (NASDAQ: ATNM) or such entities and are not necessarily indicative of future performance of Actinium Pharmaceuticals Inc. (NASDAQ: ATNM) or such entities.
Caution: Microcap stocks are not suitable for everyone, and it’s important to carefully consider your own financial goals and risk tolerance before making any investment decisions. We recommend consulting a licensed investment professional.
